Genfit lists Euronext Paris

Market cap of €464.5m

EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs, has welcomed the listing of Genfit in compartment B of Euronext’s regulated market in Paris.

Founded in 1999, with facilities in Lille (France) and Cambridge, Massachusetts (USA), Genfit is dedicated to developing therapeutic treatments and diagnostics in fields with major unmet needs, linked primarily to cardiometabolic disorders, with a particular focus on hepatitis complications including NASH. To meet these major public health concerns, Genfit is developing a portfolio of drug candidates and biomarker candidates in its own R&D programs and in programs conducted jointly with large drug companies.

Genfit (ticker symbol:GNFT) was listed through the admission to trading of the 21,257,671 existing shares making up the company’s equity under the direct listing procedure on Euronext’s regulated market in Paris.

Market capitalisation stood at around €464.5 million on the day of listing.

“We are delighted to accompany Genfit as it enters this new stage in its growth,” said Eric Forest, Chairman and CEO of EnterNext, adding “Listing will raise the company’s profile with investors and give it access to greater liquidity to step up deployment of its strategy.”

Jean-François Mouney, Chairman of Genfit’s Management Board, added “Our transfer to compartment B of NYSE Euronext Paris is set to boost Genfit’s visibility as we are integrated into a range of benchmark indices, and will also appeal to investors who prefer Euronext’s regulated market

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

WHAT IS ADVFN?

ADVFN covers all things stock market.

From the news and opinion pieces on pages like this to share discussion forums, charting tools, financials, live share prices and Level 2, order book data

If you trade or invest ADVFN has the tools you need to make the right decisions.

• 

  101 Ways to Pick Stock Market Winners

  You need the number one bestselling investment guide, the definitive text for day traders, investors and stock pickers.

• 

  The Death of Wealth

  Dissecting the global economy and the financial markets, the book lays out the evidence for the next economic game changer: the Death of Wealth.

• 

  Justin Waite

• 

  Quoted Data

• 

  Deb Shaw

• 

  Clem Chambers